This multi-center, randomized, phase II trial investigated the use of early (day 14) PET-CT to guide a switch in chemotherapy for oesophageal cancer patients with poor response to induction cisplatin/capecitabine. Non-responders were randomized to continue cisplatin/capecitabine or switch to carboplatin/paclitaxel. The trial was stopped early due to futility and potential harm. In oesophageal squamous cell carcinoma (OSCC), cisplatin/capecitabine was superior to carboplatin/paclitaxel, indicating that early metabolic response assessment is not prognostic and shouldn't guide therapy personalization in this context. Results for oesophageal adenocarcinoma were inconclusive due to small sample size.
Publisher
The Lancet
Published On
Jul 01, 2023
Authors
Somnath Mukherjee, Christopher N Hurt, Richard Adams, Andrew Bateman, Kevin M Bradley, Sarah Bridges, Stephen Falk, Gareth Griffiths, Sarah Gwynne, Christopher M Jones, Philip J Markham, Tim Maughan, Lisette S Nixon, Ganesh Radhakrishna, Rajarshi Roy, Simon Schoenbuchner, Hamid Sheikh, Emiliano Spezi, Maria Hawkins, Thomas D L Crosby
Tags
oesophageal cancer
chemotherapy
PET-CT
cisplatin
carboplatin
randomized trial
metabolic response
Related Publications
Explore these studies to deepen your understanding of the subject.
